[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648012":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":42,"locations":47,"responsibleParty":67,"collaborators":26,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":26,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":26,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":93,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Patients will receive intravenous magnesium sulfate infusion to achieve and maintain upper normal serum magnesium levels (2.0 - 2.3 mg\u002FdL).",[13],"Drug: magnesium sulfate",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","ACTIVE_COMPARATOR","Patients will receive standard care to maintain serum magnesium levels (1.7 - 1.9 mg\u002FdL).",[19],"Other: standard care treatment",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","magnesium sulfate","Intravenous magnesium sulfate infusions will be individualized and administered to achieve and maintain the target serum magnesium levels.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"standard care treatment","Patients will receive standard care required to maintain the target serum magnesium levels.",[15],[32,36,39],{"name":33,"affiliation":34,"role":35},"Noha A Hamdy, PhD","Faculty of Pharmacy, Alexandria University.","STUDY_CHAIR",{"name":37,"affiliation":38,"role":35},"Marwan M ElBourini, PhD","University of Alexandria",{"name":40,"affiliation":34,"role":41},"Asmaa K Elharony, PharmD","PRINCIPAL_INVESTIGATOR",[43],{"name":40,"role":44,"phone":45,"phoneExt":26,"email":46},"CONTACT","+201062593630","asmaa.khamis252@gmail.com",[48],{"facility":49,"status":26,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Alexandria Main University Hospital","Alexandria","Alexandria Governorate","21526","Egypt","EG",{"type":56,"coordinates":57},"Point",[58,59],29.91582,31.20176,{"lat":59,"lon":58},[62,63,64,66],{"name":40,"role":44,"phone":45,"phoneExt":26,"email":46},{"name":40,"role":41,"phone":26,"phoneExt":26,"email":26},{"name":33,"role":65,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"name":37,"role":65,"phone":26,"phoneExt":26,"email":26},{"type":68,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100648012","effect-of-targeting-upper-normal-serum-magnesium-levels-on-norepinephrine-requirements-in-septic-shock-patients-100648012",false,"NCT07716956","Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients","Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Male and female adult patients (aged ≥18 years) diagnosed with septic shock.\n* Resistant septic shock that requires corticosteroids.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Baseline hypermagnesemia (serum magnesium level \\> 2.3 mg\u002FdL).\n* Renal impairment with creatinine clearance (CrCl) \\\u003C 10 ml\u002Fmin.\n* Mixed shock.","ALL","18 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"NA","The goal of this clinical trial is to assess the effect of targeting upper normal serum magnesium levels on norepinephrine requirements in adult patients with septic shock.\n\nThe main questions it aims to answer are:\n\n1. Does maintaining upper normal serum magnesium levels lower the total cumulative dose and duration of norepinephrine therapy?\n2. Does this approach reduce the intensive care unit (ICU) length of stay, duration of mechanical ventilation and mortality?\n\nThis study will compare an intervention group to a control group to see the effect of targeting upper normal serum magnesium levels.\n\nParticipants will:\n\n* Have their serum magnesium levels assessed at baseline (Day 0), at three-day intervals (Days 3, 6, 9) thereafter and on the day of norepinephrine discontinuation.\n* Receive individualized intravenous magnesium sulfate infusions to achieve and maintain the target serum magnesium levels.\n* Have their demographic data collected and be monitored closely for clinical data, vital signs, Mean Arterial Pressure (MAP), urine output and laboratory parameters.",[86,87],"Septic Shock","Sepsis",[89,90,23,91,92],"vasopressors","norepinephrine","magnesium level","ICU ( Intensive Care Unit )","NOT_YET_RECRUITING","2026-07-16",{"date":96,"type":97},"2026-07-21","ACTUAL",{"date":99,"type":80},"2026-07",{"date":101,"type":80},"2027-07",{"name":5,"class":6},1]